AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03535350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: Cycle 1 150mg/m2 and cycle 2-6 will be up to 200mg/m2.
Study NCT03224013 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK
Description: LASIK with concurrent prophylactic high fluence crosslinking in right eye ( After the excimer laser ablation, and with the flap folded onto itself and protected with a dry sponge, one drop of Vibex Rapid™ , consisting of 0.10% saline-diluted riboflavin (a very slightly hypotonic solution, mixed with hydroxypropyl methylcellulose, a dextran substitute), was placed on the exposed stromal bed afforded by the open LASIK flap and carefully spread over the bed area with an irrigating cannula for 60 seconds and LASIK only in left eye
Study NCT02386657 — intervention group
Intervention type: OTHER
Intervention: Satisfaction
Description: Satisfaction questionnaire to be filled in
Study NCT02386657 — intervention group
Intervention type: OTHER
Intervention: Biological parameters
Description: Measure of standard routine biological parameters (Hb, GB, Plaq, LDH, CRP, TCA, INR, D Dimers) and dosage of nitrous albumin (PNA).
Study NCT03220295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dose Escalation
Description: dose levels of the cohorts will be increased step wise
Study NCT02386657 — intervention group
Intervention type: OTHER
Intervention: Pain management
Description: Validated pain scale questionnaire to be filled in
Study NCT02124343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Exercise
Study NCT03879408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 440 mg naproxen sodium with 1000 mg acetaminophen
Description: 440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
Study NCT03879408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 220 mg naproxen sodium with 650 mg acetaminophen
Description: 220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
Study NCT03879408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg hydrocodone + 650 mg acetaminophen
Description: 10 mg hydrocodone with 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
Study NCT03879408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 440 mg naproxen sodium
Description: 440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
Study NCT03879408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Single dose of four placebo tablets
Study NCT03072589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson infusion
Description: Dose escalation of Regadenoson when given as an infusion
Study NCT02714595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: 2 g intravenously over 3 hours every 8 hours for a period of 7 to 14 days, or 2 g every 6 hours for participants with creatinine clearance >120 mL/min.
Study NCT02714595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy
Description: Standard of care with either a polymyxin-based or non-polymyxin-based regimen as determined by the investigator and consisting of one to three marketed antibacterial agent(s).
Study NCT03958838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support Integrated with Primary Care
Description: Peer leaders will deliver support that address the four key functions of peer support, providing 1) assistance in daily self-management, 2) linkages to clinical care and community resources, 3) social and emotional support, and 4) ongoing, flexible support over time.
Study NCT00671528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)
Description: Betamethasone diproprionate 0.05%, clotrimazole 1%, and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area 2 times a day (BID), morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
Study NCT00671528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cream (betamethasone diproprionate and gentamicin)
Description: Betamethasone diproprionate 0.05% and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
Study NCT00671528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cream (betamethasone diproprionate)
Description: Betamethasone diproprionate 0.05% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
Study NCT04468269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task oriented balance training with sensory integration group
Description: Sitting position:~1. Sit in a chair without backrest while keeping the feet on floor.~2. Sit on a ball while keeping the feet on the floor.~Sit to stand:~1. Sit in a chair without a backrest~2. Sit in a chair without a backrest with and perform the sit-to-stand motion repeatedly.~3. Sit on a ball and perform the sit-to-stand motion repeatedly.~Standing position:~Perform bipedal standing Control Of Weight Shifting. Perform a semi-tandem stance. One Foot Standing.~Walking:~1. Walk forward~2. Walk forward cross an obstacle, and then continue to walk.~3. Walk Lateral~4. Walk Backward~5. Tandem walk
Study NCT04468269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task oriented balance training without sensory integration group
Description: Sitting position:~1. Sit in a chair without a backrest while keeping the feet on a firm surface.~2. Sit on a ball while keeping the feet on the firm surface~Sit to stand:~1. Sit in a chair without a backrest with the feet on a firm surface and perform the sit-to-stand motion repeatedly.~2. Sit on a ball with the feet on the firm surface and perform the sit-to-stand motion repeatedly.~Standing position:~1. Perform bipedal standing on a firm surface.~2. Perform a semi-tandem stance on the firm surface~Walking:~1. Walk forward on a firm surface.~2. Walk forward on the firm surface, cross an obstacle, and then continue to walk.~3. Walk sideways~4. Walk Backward~5. Tandem walk
Study NCT03088709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV medication given for prevention of graft versus host disease.
Study NCT03088709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: IV medication given for prevention of graft versus host disease.
Study NCT03088709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: IV medication given for prevention of graft versus host disease.
Study NCT03088709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haploidentical Stem Cell Transplantation
Description: A stem cell transplant that involves matching a patient's tissue type, specifically their human leukocyte antigen (HLA) tissue type, with that of a related donor.
Study NCT02913664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)
Description: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine) will be used to reduce SBP\<130 mmHg; atorvastatin 80 mg daily will be administered to reduce blood lipid level. Additional antihypertensives may be used if needed.~Intensive Reduction of Vascular Risk Factors (IRVR)
Study NCT02913664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Participants will take part in a supervised, moderate to vigorous aerobic exercise training program for approximately 24 months. This program consists of exercising 3 times per week for about 30 minutes per session at the beginning, and will increase to 4-5 times per week, 40-50 minutes per session over a period of 4-5 months. Exercise frequency, intensity and duration will be maintained at this level during the rest of the study period.
Study NCT02913664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will follow their regular doctor's recommendations for blood pressure and lipid control.
Study NCT02913664 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participants will follow their regular doctor's recommendations for blood pressure and lipid control.
Study NCT01906307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJPC-501
Description: Patients will receive LJPC-501 at titrated doses, with a starting range from 1 to 100 ng/kg/min, by continuous infusion on Days 1 through 5. In Group 1, drug doses will be titrated to 5, 15, and 25 ng/kg/min, after which doses will be titrated in multiples of 25 ng/kg/min. In Groups 2-5, drug doses will be titrated by 25 ng/kg/min. Dose titrations will occur every 2 hours until a MAP of 110 mmHg is reached, maximum urine output is achieved, or a dose of 250 ng/kg/min is achieved. Dosing will then continue at the maximum dose achieved through Day 5.
Study NCT02511067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Intravenous Infusion of Tocilizumab ( 8.0 mg/kg)
Study NCT02511067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal injection of Ranibizumab (0.3mg)
Study NCT02511067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection of Ranibizumab (0.3mg)
Study NCT02913664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching Exercise
Description: Participants will perform home-based stretching exercise 3 times per week, gradually increased to 4-5 times per week over a period of 4-5 months, and maintained at this level during the rest of the study period. They will be encouraged to attend monthly stretching exercise classes, which will be led by study staff or exercise trainers.
Study NCT02913664 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching Exercise
Description: Participants will perform home-based stretching exercise 3 times per week, gradually increased to 4-5 times per week over a period of 4-5 months, and maintained at this level during the rest of the study period. They will be encouraged to attend monthly stretching exercise classes, which will be led by study staff or exercise trainers.
Study NCT04181762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab
Description: STUDY DRUG
Study NCT04181762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03371017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle
Study NCT03371017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle
Study NCT03371017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
Study NCT03371017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
Study NCT03995108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavorixafor
Description: Mavorixafor provided as 100 mg capsules.
Study NCT03995108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mavorixafor
Description: Mavorixafor provided as 100 mg capsules.
Study NCT03995108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to mavorixafor capsules
Study NCT03337607 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rESWT
Description: rESWT will be performed as follows:~* Four rESWT sessions~* One rESWT session per week~* 4 × 1000 radial extracorporeal shock waves (rESWs) per session (1000 rESWs each applied to the left and the right paravertebral muscles above L3 to S1 using the 36-mm applicator, plus 1000 rESWs each applied to the left and the right sacroiliac joint using the 15-mm convex applicator, in prone position of the patient.~* rESWs applied at 15 Hz~* Air pressure of the rESWT device gradually increased during the first 200 rESWs each until the maximum discomfort the patient can tolerate will be reached, followed by 800 rESWs at this air pressure / energy flux density.~* No application of local anaesthetics
Study NCT03337607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: 1 x 200 mg per day for moderate pain (Numerical Rating Scale score 4-6 on an 11-point scale where 0 indicates no pain and 10 indicates worst imaginable pain), or 2 x 200 mg per day (Numerical Rating Scale 7-10), respectively, for four weeks
Study NCT03337607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eperisone
Description: 3 x 50 mg per day for four weeks
Study NCT03371017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle
Study NCT03371017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle
Study NCT05440370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MegaCarti®
Description: MegaCarti® application after microfracture through athroscopic or incision surgery
Study NCT05440370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture
Description: Microfracture through athroscopic or incision surgery
Study NCT05440370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Microfracture through athroscopic or incision surgery
Study NCT01220700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triclosane
Description: Triclosane coated suture material
Study NCT01220700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Ordinary suture material
Study NCT01786902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-3002
Study NCT01091948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation with Fiberoptic laryngoscope
Description: Subjects will be intubated with the Fiberoptic laryngoscope.
Study NCT01091948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GlideScope® Video Laryngoscope
Description: Patients will be intubated with the GlideScope® Video Laryngoscope.
Study NCT04371146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 35 mg methylphenidate (Ritalin®) is administered once using a randomized placebo-controlled between subject's design
Study NCT04371146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reboxetine
Description: 8 mg Reboxetine (Edronax®) is administered once using a randomized placebo-controlled between subject's design
Study NCT04371146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: A placebo pill is administered once using a randomized placebo-controlled between subject's design
Study NCT02161302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device Soterix 1X1). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA current.
Study NCT02161302 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 20 minutes that the session lasts.
Study NCT02536365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Integration Therapy
Description: Children in the SIT treatment group will receive a manualized SIT intervention that follows the principles of sensory integration.
Study NCT02536365 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Applied Behavioral Analysis
Description: Children in the ABA treatment group will receive intervention that follows the principles of Applied Behavioral Analysis.
Study NCT04162093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uretero ileal anastomosis in single trough
Study NCT02493296 — intervention group
Intervention type: OTHER
Intervention: This observational study will not entail an intervention.
Description: This study will entail measurement of central aortic haemodynamics before and after (clinically indicated) abdominal aortic aneurysm repair
Study NCT01795365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active surveillance
Study NCT01795365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active surveillance
Study NCT03017079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: semi-solid agent with standard enteral feeding
Description: after infusion of semi-solid agent, Intermittent enteral feeding is applied less than 60 minutes
Study NCT03017079 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard enteral feeding
Description: Intermittent enteral feeding is applied less than 60 minutes
Study NCT03403348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
Study NCT02804347 — intervention group
Intervention type: DEVICE
Intervention: Cognitive Function Imaging and Battery
Description: Individuals will be placed in the fMRI scanner and complete the NBACK Cognitive Task
Study NCT03371017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
Study NCT03371017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
Study NCT02804347 — intervention group
Intervention type: DEVICE
Intervention: Sniffin Sticks
Description: Using Sniffin Sticks, olfactory functioning will be assessed using three tests: identification, discrimination, and threshold.
Study NCT03403348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
Study NCT02296554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLAP Repair
Description: SLAP repair for SLAP tear
Study NCT02296554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biceps Tenodesis
Description: Biceps tenodesis for SLAP tear
Study NCT01637103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive therapy of depression
Description: Cognitive therapy will involve eight individual weekly sessions of 50 minutes with a Ph.D. student in psychology.
Study NCT01637103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Description: Bright light therapy will consist of a 30-min daily morning exposition to a 10 000-lux BLT lamp during 8 weeks.
Study NCT02021175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored CBME Therapy via Technology
Description: 6 Sessions of tailored interactive Cognitive-Behavioral Motivational Enhancement Therapy delivered through internet and cell phones
Study NCT02021175 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Referral to currently available resources for 6 sessions of a standard smoking cessation approach
Study NCT03204955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride /sodium acetate (16.4%)
Description: Sodium Acetate is a sterile, nonpyrogenic solution of Sodium Acetate intended as an alternative to sodium chloride to provide sodium ion in parenteral (IV) fluid therapy.~Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy.